Cargando…

Correction to: Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Corrections
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809997/ https://www.ncbi.nlm.nih.gov/pubmed/35947868 http://dx.doi.org/10.1093/schbul/sbac104

Ejemplares similares

Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
por: Taipale, Heidi, et al.
Publicado: (2022)

Choosing an Optimal Antipsychotic Dose for Relapse Prevention
por: Davis, John M, et al.
Publicado: (2022)

Correction: Antipsychotic medications and stroke in schizophrenia: A case-crossover study
por: Chen, Wen-Yin, et al.
Publicado: (2019)

Correction to: A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Publicado: (2022)

Correction: Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction)
Publicado: (2020)

Correction: Prognostic factors for relapse in patients with clinical stage I testicular cancer: protocol for a Danish nationwide cohort study
Publicado: (2019)

Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics
por: Kishimoto, Taishiro, et al.
Publicado: (2011)

Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
por: García-Ruiz, Antonio J, et al.
Publicado: (2012)

Correction to: The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey
por: Tandon, Rajiv, et al.
Publicado: (2020)

Depot Typical Antipsychotics versus Oral Atypical Antipsychotics in Relapse Rate Among Patients with Schizophrenia: A Five -Year Historical Cohort Study
por: Ahmadkhaniha, Hamid-Reza, et al.
Publicado: (2014)

Correction to: Assessment of Psychosocial Functioning in a Large Cohort of Patients with Schizophrenia
por: Kossmann, C., et al.
Publicado: (2022)

Correction: Hyperprolactinemia with antipsychotic drugs in children and adolescents
por: Rosenbloom, Arlan L
Publicado: (2013)

Evaluation of the Individual Safe Correction of Antipsychotic Agent Polypharmacy in Japanese Patients with Chronic Schizophrenia: Validation of Safe Corrections for Antipsychotic Polypharmacy and the High-Dose Method
por: Yamanouchi, Yoshio, et al.
Publicado: (2015)

Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia
por: Morken, Gunnar, et al.
Publicado: (2008)

Antipsychotic dose reduction compared to dose continuation for people with schizophrenia
por: Rodolico, Alessandro, et al.
Publicado: (2022)

Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics
por: Pilon, Dominic, et al.
Publicado: (2021)

The Cumulative Effect of Antipsychotic Usage on Mortality in Schizophrenia: A Nationwide Population-based Cohort Study in Korea
por: Kim, Gyurin, et al.
Publicado: (2022)

Correction to: Use of Nonrecommended Drugs in Patients With Brugada Syndrome: A Danish Nationwide Cohort Study
Publicado: (2023)

Correction to: Risk factors for relapse in patients with first-episode schizophrenia: analysis of the Health Insurance Review and Assessment Service data from 2011 to 2015
por: Lee, Sang‑Uk, et al.
Publicado: (2018)

Risk factors for psychotic relapse in chronic schizophrenia after dose-reduction or discontinuation of antipsychotics. A systematic review and meta-analysis
por: Bogers, J., et al.
Publicado: (2021)

Author Correction: Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics
por: Boloc, Daniel, et al.
Publicado: (2019)

Correction to: Risk of Adverse Outcomes for Older People with Dementia Prescribed Antipsychotic Medication: A Population Based e-Cohort Study
por: Dennis, Michael, et al.
Publicado: (2018)

Correction: A Prospective Cohort Study of Antipsychotic Medications in Pregnancy: The First 147 Pregnancies and 100 One Year Old Babies
por: Kulkarni, Jayashri, et al.
Publicado: (2023)

Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study
por: Geitona, Maria, et al.
Publicado: (2009)

Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia
por: Yu, Chia-Ling, et al.
Publicado: (2023)

Publisher Correction: Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma
por: Reutter, Katrin, et al.
Publicado: (2021)

Correction: Risk of chronic kidney disease in patients with heat injury: A nationwide longitudinal cohort study in Taiwan
Publicado: (2020)

T246. RISK FACTORS FOR PSYCHOTIC RELAPSE IN CHRONIC SCHIZOPHRENIA AFTER DOSE-REDUCTION OR DISCONTINUATION OF ANTIPSYCHOTICS: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Bogers, Jan, et al.
Publicado: (2020)

Correction: How Prevalent Is Schizophrenia?
Publicado: (2019)

Correction to: Service Users’ Views and Experiences of Alcohol Relapse Prevention Treatment and Adherence: New Role for Pharmacists?
por: Dhital, Ranjita, et al.
Publicado: (2022)

Correction: Predictors of physical activity among older adults in Germany: a nationwide cohort study
Publicado: (2019)

Correction: Preeclampsia and risk of end stage kidney disease: A Swedish nationwide cohort study
por: Khashan, Ali S., et al.
Publicado: (2019)

Correction: The risk of newly diagnosed cancer in patients with rheumatoid arthritis by TNF inhibitor use: a nationwide cohort study
por: Choi, Boyoon, et al.
Publicado: (2022)

Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics With Disease Relapse, Health Care Use, and Adverse Events Among People With Schizophrenia
por: Wei, Yue, et al.
Publicado: (2022)

Correction to: Patient and Physician Reported Perception on Hypercholesterolemia Management in Primary Prevention in Germany: Results from a Nationwide Online Survey
por: Beier, Lea, et al.
Publicado: (2022)

Correction to: Antipsychotics and dementia in Canada: a retrospective cross-sectional study of four health sectors
por: Rios, Sebastian, et al.
Publicado: (2018)

Polypharmacy Management of Antipsychotics in Patients with Schizophrenia
por: Kamei, Hiroyuki
Publicado: (2022)

Correction to: Cladribine Tablets: A Review in Relapsing MS
por: Deeks, Emma D.
Publicado: (2019)

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
por: Kroschinsky, Frank, et al.
Publicado: (2020)

Effects of Antipsychotics on Arrhythmogenic Parameters in Schizophrenia Patients: Beyond Corrected QT Interval
por: Okayasu, Hiroaki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9440p0l1f92fan9tmi4hl16amh